Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids
by Zacks Equity Research
Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.
Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab
by Zacks Equity Research
An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
by Kinjel Shah
Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.
Top 5 Low-Beta High-Yielding Stocks to Counter Volatility
by Nalak Das
We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, PKG, ATO, TXN and CCI.
Zacks.com featured highlights include Crocs, Sonic Automotive, Pfizer, ExxonMobil and KB Home
by Zacks Equity Research
Crocs, Sonic Automotive, Pfizer, ExxonMobil and KB Home are included in this blog.
TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.
AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.
Boost Your Returns With These 5 High Earnings Yield Stocks
by Rimmi Singhi
Crocs (CROX), Sonic Automotive (SAH), Pfizer (PFE), ExxonMobil (XOM) and KB Home (KBH) are some top-ranked stocks boasting high earnings yield.
Best Growth Stocks to Buy for February 9th
by Zacks Equity Research
AAPL, PFE, and APA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 9, 2022
The Zacks Analyst Blog Highlights Amgen, TakeTwo Interactive, Chegg, Pfizer and BP
by Zacks Equity Research
Amgen, TakeTwo Interactive, Chegg, Pfizer and BP are included in this blog.
Best Growth Stocks to Buy for February 8th
by Zacks Equity Research
CROX, PFE, and CLS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 8, 2022
Markets Await More Earnings Data
by Zacks Equity Research
Markets Await More Earnings Data
Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.
NVIDIA/ARM Deal Off, Peloton CEO Steps Down
by Mark Vickery
Tech giant NVIDIA's (NVDA) planned acquisition of Softbank entity Arm Software is no more.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DIV
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat
by Mark Vickery
After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
Best Growth Stocks to Buy for February 7th
by Zacks Equity Research
AAPL, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 7, 2022
Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer
by Zacks Equity Research
AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.
How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
by Sundeep Ganoria
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.